

Langebrake et al. (23), Lapillonne et al. (24), and Hess et al. (25). The FAB classification scheme is also used for the MDS (26) but in one specific context, that is, for predicting progression MDS to AML.

Cancerous cells in the various leukemias, and cancer cells in the various MDS, can be distinguished from each other by cytogenetics and by flow cytometry (27). The cytogenetics of ALL (28), CLL (29), AML (30), CML (31), and MDS (32,33), have been reviewed, as cited.

The nomenclature used for identifying the cytogenetics of the hematological malignancies has been standardized, and is periodically revised (34,35). The standard nomenclature is the *International System for Human Cytogenetic Nomenclature* (ISCN).

Flow cytometry, reviewed by Belov et al. (36), uses the CD nomenclature. The CD nomenclature can be used to distinguish between the various hematological cancers. "CD" stands for cluster of differentiation

²³Langebrake C, Creutzig U, Dworzak M, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. *J. Clin. Oncol.* 2006;24:3686–92.

²⁴Lapillonne H, Renneville A, Auvrignon A, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. *J. Clin. Oncol.* 2006;24:1507–15.

²⁵Hess CJ, Berkhof J, Denkers F, et al. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. *J. Clin. Oncol.* 2007;25:1209–15.

²⁶Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. *Blood* 2007;110:4385–95.

²⁷Wood BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. *Cytometry B Clin. Cytom.* 2015. doi:10.1002/cyto.b.21239.

²⁸Wetzler M. Cytogenetics in adult acute lymphocytic leukemia. *Hematol. Oncol. Clin. North Am.* 2000;14:1237–49.

²⁹Higgins RA, Gunn SR, Robetorye RS. Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia. *Mol. Diagn. Ther.* 2008;12:271–80.

³⁰Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. *J. Hematol. Oncol.* 2009;2:23.

³¹Tefferi A, Dewald GW, Litzow ML, et al. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. *Mayo Clin. Proc.* 2005;80:390–402.

³²Costa D, Valera S, Carrió A, et al. Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do? *Leuk. Res.* 2010;34:1437–41.

³³Steensma DP, List AF. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. *Mayo Clin Proc.* 2005;80:681–98.

³⁴Shaffer LG, Slovak ML, Campbell LJ, editors. *ISCN 2009: an International System for Human Cytogenetic Nomenclature (2009): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature*, Karger, Switzerland; 2009.

³⁵Brothman AR, Persons DL, Shaffer LG. Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition. *Cytogenet. Genome Res.* 2009;127:1–4.

³⁶Belov L, de la Vega O, dos Remedios CG, Mulligan SP, Christopherson RI. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. *Cancer Res.* 2001;61:4483–9.